Source comparison
Effectiveness Comparison
Clinical evidence for Thymosin Alpha-1 spans multiple Phase II and Phase III trials across various therapeutic indications[28]. The landmark Phase III trial for chronic hepatitis B (NCT00001230) enrolled 234 patients and demonstrated sustained virological resp
This comparison does not assign a generated winner or score.
- Clinical evidence for Thymosin Alpha-1 spans multiple Phase II and Phase III trials across various therapeutic indications[28]. The landmark Phase III trial for chronic hepatitis B (NCT00001230) enrolled 234 patients and demonstrated sustained virological response rates of 42% with Thymosin Alpha-1 versus 25% with placebo at 24-week follow-up[29]. In oncology applications, the Phase II NSCLC trial (NCT01344109) showed improved overall survival of 13.2 months versus 9.8 months in the control group when Thymosin Alpha-1 was combined with chemotherapy[30]. A meta-analysis of 12 randomized controlled trials involving 1,892 patients revealed significant improvements in immune function markers, with CD4+ T-cell counts increasing by an average of 89 cells/μL compared to baseline[31].
- TB-500 effectiveness data remains limited to preclinical animal studies and anecdotal reports, as no human clinical trials have been completed[32]. In a rat myocardial infarction model, TB-500 administration at 6 mg/kg twice weekly for 4 weeks improved left ventricular ejection fraction by 23% compared to saline controls[33]. Wound healing studies in diabetic mice demonstrated 35% faster epithelialization rates and 2.1-fold increased collagen deposition with TB-500 treatment versus controls[34]. However, these animal study results cannot be directly extrapolated to human efficacy without proper clinical validation[35].
- Human clinical trials
- 15+ Phase II/III studies
- None completed
- Hepatitis B response
- 42% sustained response (Phase III)
- No human data
- Cancer survival benefit
- +3.4 months OS (Phase II)
- Immune function
- +89 CD4+ cells/μL (meta-analysis)
- Wound healing
- Limited human data
- 35% faster (mouse model)
- Cardiovascular
- No specific trials
- 23% LVEF improvement (rat)